Lars Fruergaard Jorgensen, Novo Nordisk CEO (Photographer: Chris Ratcliffe/Bloomberg via Getty Images)
November 22, 2022 03:14 PM ESTUpdated November 23, 06:20 AM
Pharma
Manufacturing

No­vo Nordisk to spend $747M+ on ex­pan­sions and new fa­cil­i­ty in Den­mark

Tyler Patchen

News Reporter

The Dan­ish phar­ma gi­ant No­vo Nordisk is mak­ing a ma­jor ex­pan­sion close to home.

The com­pa­ny an­nounced on Tues­day that it plans to in­vest 5 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

Nether­lands pours $1.5B in­to biotech in pur­suit of glob­al lead­er­ship am­bi­tions

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times